profit from every $100 of sales.
$0$100
Cerus
$1.99+2.32% today
+24.1% in 1 year
1-year low $1.491-year high $3.28
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cerus sold, what it kept, and what it did with the cash.
Sales went from $162 million in 2022 to $206 million in 2025, with -$15.6 million of profit last year.
SalesProfit
Cerus vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cerus | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads Cerus's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 162 | 156 | 180 | 206 | |
| 87 | 86 | 100 | 112 | |
| -34 | -26 | -14 | -9 | |
| -34 | -26 | -10 | -6 | |
| -43 | -37 | -21 | -16 | |
| -0.24 | -0.21 | -0.11 | -0.08 | |
| 53.7% | 55.3% | 55.2% | 54.5% | |
| -21.0% | -16.8% | -7.9% | -4.2% | |
| -26.4% | -24.0% | -11.6% | -7.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 218 | 198 | 201 | 222 |
| Cash | 36 | 12 | 20 | 20 |
| Total debt | 87 | 96 | 98 | 97 |
| Total liabilities | 150 | 144 | 144 | 157 |
| 68 | 53 | 56 | 64 | |
| 177 | 180 | 185 | 191 | |
| -18.6% | -15.4% | -6.1% | -3.4% | |
| -63.3% | -71.2% | -37.3% | -24.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -26 | -43 | 11 | 5 | |
| 2 | 5 | 3 | 4 | |
| -28 | -48 | 9 | 1 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 24 | 20 | 23 | 23 |
Valuation
- –
- –
- –
- 8.7×
- 1.9×
- 361.8×
- –
- 0.3%
- -3.9%
- 0.0%
Profitability
- 54.5%
- -4.2%
- -7.6%
- -6.5%
- -10.3%
- -21.5%
- -15.4%
- -4.3%
- -15.3%
- 29.5%
Growth
- +8.4%
- –
- +0.0%
- –
- +2.7%
Financial health
- –
- 1.44
- 43.7%
- -2.2×
- 1.63
- 1.06
- 1.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 27%of 946
Bottom 18%of 871
Bottom 40%of 867
Bottom 42%of 986
What analysts expect
- Average price target
- $4.00
- Range
- $4.00 – $4.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.01 | -0.03 | +66.7% |
| Mar 2, 2026 | -0.01 | -0.01 | +0.0% |
| Nov 6, 2025 | -0.00 | -0.02 | +99.5% |
| Aug 5, 2025 | -0.03 | -0.02 | −50.0% |
| May 1, 2025 | -0.04 | -0.05 | +20.0% |
| Feb 20, 2025 | -0.01 | -0.01 | +0.0% |
| Oct 30, 2024 | -0.02 | -0.02 | −33.3% |
| Aug 1, 2024 | -0.03 | -0.02 | −25.0% |
News
Cerus reaffirms $229M-$231M 2026 product revenue as it now expects CE Mark clearance in late 2027Seeking Alpha · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
19No pass
Philip Fisher
28No pass
Peter Lynch
29No pass
Joel Greenblatt
0No pass
Charlie Munger
18No pass
Terry Smith
21No pass
Questions about Cerus
Is Cerus a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cerus AI analysis
What does Cerus do?
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. It is in Medical - Devices.
Does Cerus pay a dividend?
No. Cerus does not pay a dividend at the moment.
Is Cerus stock halal?
Yes. Cerus passes our halal screen: its business is permitted and its debt is 24% of its market value, under the 30% limit. How we check
How has Cerus stock done over the past year?
Up 24.1% over the past twelve months, to $1.99. It traded between $1.49 and $3.28 and is 39.5% below its high.
Who are Cerus's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Cerus's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.